Company Overview

Nectar Lifesciences Limited (NSE: NECLIFE, BSE: 532649) has undergone significant corporate restructuring and strategic transformation during FY 2025-26, culminating in the notice for its 31st Annual General Meeting scheduled for September 18, 2026.

Major Business Restructuring

The company executed comprehensive asset monetization initiatives including:

Pharmaceutical Business Divestment: Completed slump sale of Active Pharmaceutical Ingredients business (Units 1 & 2, Derabassi) and Formulation business (Unit 6, Baddi) to Ceph Lifesciences Private Limited for ₹12,539.86 million (after working capital adjustments), resulting in an exceptional gain of ₹1,633.73 million. The transaction was completed on November 10, 2025.

Additional Asset Sales:

  • Menthol assets sold for ₹200.00 million (fully received)
  • Capsule business transfer to Capnest Health Care for ₹199.00 million (pending government approval)
  • Jammu unit assets and Garhshankar land identified for monetization

Financial Performance

FY26 results reflect the transformational year:

  • Revenue from Operations: Nil (post-business divestment)
  • Other Income: ₹92.91 million
  • Net Loss: ₹2,928.85 million despite exceptional gain
  • Discontinued Operations Loss: ₹2,355.44 million
  • Earnings Per Share: (₹13.40) basic and diluted
  • Cash Position: ₹1,121.35 million as of March 31, 2026
  • Total Cash Inflow: Approximately ₹12.74 billion from asset sales

The company executed a ₹810 million share buyback at ₹27 per share, reducing share capital by ₹30 million and transferring ₹780 million from securities premium account.

Strategic Shift and Corporate Development

Nectar Lifesciences has fundamentally transformed its business model:

  • Amended Memorandum of Association to include real estate activities
  • Acquired 100% of Avensis Exports Private Limited for real estate expansion
  • Shifted from pharmaceuticals to real estate development focus
  • Evaluating further non-core asset monetization opportunities

Corporate Governance and AGM Matters

The 31st AGM will address several key resolutions:

  • Approval of FY26 financial statements and annual report
  • Re-appointment of Mr. Sanjiv Goyal as Director
  • Re-appointment of independent directors Dr. Kuldip Kumar Bhasin and Dr. Indu Pal Kaur
  • Appointment of Dr. Gunmala Suri as Non-Executive Non-Independent Director
  • Other routine corporate matters

AGM will be held virtually on September 18, 2026, with e-voting available from September 15-17, 2026. Book closure period is September 12-18, 2026.

Regulatory Compliance and Governance

The company maintained compliance with SEBI Listing Regulations and Companies Act requirements:

  • Board met 9 times during FY25-26
  • All independent directors provided required independence declarations
  • CSR expenditure of ₹2.08 million despite net losses
  • Whistleblower mechanism in place with no complaints during the year

Future Outlook

With the pharmaceutical business divestment complete and significant cash resources available, Nectar Lifesciences is positioned to pursue new opportunities in real estate development while continuing to monetize remaining non-core assets. The strategic shift represents a fundamental transformation of the company's business model and market positioning.